Lucia Brunello
Overview
Explore the profile of Lucia Brunello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stella F, Pennisi M, Chiappella A, Casadei B, Bramanti S, Ljevar S, et al.
Transplant Cell Ther
. 2025 Jan;
PMID: 39870308
Background: Anti-CD19 CAR T-cells have revolutionized outcomes in relapsed/refractory large B-cell lymphomas. Long-term follow-up underscored the role of hematological toxicity in nonrelapse mortality, largely driven by infections, leading to the...
2.
Malagola M, Castagna L, Farina M, Pellizzeri S, Degrandi E, Oldani E, et al.
Leuk Lymphoma
. 2025 Jan;
1-4.
PMID: 39813626
No abstract available.
3.
Corcione S, Ferrocino I, Lupia T, Busca A, Bianco G, Dellacasa C, et al.
Sci Rep
. 2025 Jan;
15(1):1275.
PMID: 39779737
After allogeneic HSCT (allo-HSCT), the diversity of the intestinal microbiota significantly decreases. The changes can be rapid and are thought to be caused by chemotherapy, antibiotics, or intestinal inflammation. Most...
4.
5.
6.
Barone A, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, et al.
Br J Haematol
. 2024 Jun;
205(4):1356-1360.
PMID: 38877876
Secondary primary malignancies (SPM) have been reported after anti-BCMA or anti-CD19 chimeric antigen receptor (CAR)-T-cell therapies. While the cytotoxic effect of antecedent therapies, including chemotherapy and radiotherapy, has been well...
7.
Penack O, Peczynski C, Boreland W, Lemaitre J, Afanasyeva K, Kornblit B, et al.
Front Immunol
. 2023 Dec;
14:1283034.
PMID: 38149251
Introduction: Extracorporal Photophoresis (ECP) is in clinical use for steroid-refractory and steroid-dependent acute GVHD (SR-aGVHD). Based on recent Phase-III study results, ruxolitinib has become the new standard of care for...
8.
9.
Butera S, Tavarozzi R, Brunello L, Rivela P, Sofia A, Viero L, et al.
J Basic Clin Physiol Pharmacol
. 2023 Oct;
34(6):805-809.
PMID: 37843253
Objectives: Graft-versus-host disease (GVHD) of central nervous system is an atypical and rare manifestation of chronic GVHD, presenting with a heterogeneous spectrum of signs and symptoms. Diagnosis of neurological manifestations...
10.